Breast imaging device developer TransScan of Ramsey, NJ, has expanded chairman Hal Kirshner’s duties to include those of president and CEO. Kirshner joined TransScan in May 1999. Before that he had served as president and CEO of Trex Medical and
Breast imaging device developer TransScan of Ramsey, NJ, has expanded chairman Hal Kirshners duties to include those of president and CEO. Kirshner joined TransScan in May 1999. Before that he had served as president and CEO of Trex Medical and president of Trex subsidiary Lorad (SCAN 5/12/99).
Under Kirshners chairmanship, TransScan received premarket approval clearance from the Food and Drug Administration for improvements in the design and operation of its TS-2000 electrical impedance breast scanning system (SCAN 11/24/99). The FDA initially cleared the unit last April for use as an adjunct to mammography for follow-up exams in patients with equivocal mammograms.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.